A Phase II Study of AP (Doxorubicin, Cisplatin) Chemotherapy in Patients with Advanced Hepatocellular Carcinoma.
- Author:
Jung Ae LEE
1
;
Yoon Koo KANG
;
Chang Min KIM
;
Jin Oh LEE
;
Tae Woong KANG
Author Information
1. Department of Internal Medicine, College of Medicine, Hallym University, Korea.
- Publication Type:Original Article
- Keywords:
Advanced hepatocellular carcinoma;
Chemotherapy;
Adriamycin;
Cisplatin
- MeSH:
Carcinoma, Hepatocellular*;
Cisplatin;
Doxorubicin;
Drug Therapy*;
Drug Therapy, Combination;
Humans;
Prognosis
- From:Journal of the Korean Cancer Association
1997;29(1):103-110
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Hepatocellular carcinoma (HCC) is the most common form of primary hepatic carcinoma and is considered to be a highly malignant tumor with poor prognosis. We evaluated the efficacy and toxicities of AP (doxorubicin, cisplatin) comnination chemotherapy in hepatocellular carcinoma. MATERIALS AND METHODS: Between October 1989 and February 1991, 21 previously untreated patients with advanced hepatocellular carcinoma were entered and treated with AP combination chemotherapy (adriamycin 60 mg/m2, D1 and cisplatin 60 mg/m2, D1, repeated every 3 weeks). RESULTS: Among 14 evaluable patients, there was no complete response and 5 patients (36%; 95% C.I=10~62%) achieved partial response. The median survival time of all 21 patients was 17 weeks, and 63 weeks in responders (n=5) and 14 weeks in nonresponders (n=16), and the difference in two groups was statistically significant (p<0.05). The median time to progression of 14 evaluable patients was 13 weeks, and 49 weeks in the responders (n=5) and 6 weeks in the nonresponders (n=9), and the difference in two groups was statistically significant (p<0.05). Myelosuppression was minimal and non-hematologic toxicities were gererally mild and well tolerated. CONCLUSION: The results suggest that the combination chemotherpy of AP seems to be an effective regimen for hepatocellular carcinoma. Further trials are recommended for its true efficacy.
